Published in Oncotarget on May 10, 2015
Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma. Oncotarget (2016) 0.81
Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted Therapy. Front Oncol (2016) 0.79
Choline Metabolism Alteration: A Focus on Ovarian Cancer. Front Oncol (2016) 0.76
CHKA mediates the poor prognosis of lung adenocarcinoma and acts as a prognostic indicator. Oncol Lett (2016) 0.75
Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. Front Oncol (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20
Glutathione metabolism and its selective modification. J Biol Chem (1988) 4.89
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A (2011) 3.66
Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat Rev Cancer (2013) 3.23
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A (1992) 3.22
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia (2009) 2.43
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol (2007) 2.35
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Choline kinase inhibition in rheumatoid arthritis. Ann Rheum Dis (2014) 2.17
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun (2002) 2.09
Glutathione monoethyl ester: preparation, uptake by tissues, and conversion to glutathione. Arch Biochem Biophys (1985) 1.82
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One (2011) 1.35
Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene (2009) 1.28
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs (2010) 1.25
Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med (2009) 1.21
Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res (2008) 1.19
MR evaluation of response to targeted treatment in cancer cells. NMR Biomed (2011) 1.14
A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene (2011) 1.09
Role of glutathione in cancer pathophysiology and therapeutic interventions. J Exp Ther Oncol (2012) 1.04
Glutathione levels in human tumors. Biomarkers (2012) 1.02
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer (2013) 0.96
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway. Cancer Res (2014) 0.96
IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res (2014) 0.94
The changing landscape of therapeutic strategies for recurrent ovarian cancer. Future Oncol (2012) 0.89
Strategies to improve the efficacy of platinum compounds. Curr Med Chem (2009) 0.87
Metabolic imaging of pancreatic ductal adenocarcinoma detects altered choline metabolism. Clin Cancer Res (2014) 0.86
Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br J Cancer (2013) 0.85
GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis models. Hum Mol Genet (2011) 0.84
Elevation of cysteine consumption in tamoxifen-resistant MCF-7 cells. Biochem Pharmacol (2012) 0.84
Choline metabolic profiling by magnetic resonance spectroscopy. Methods Mol Biol (2013) 0.82
Rheumatoid arthritis: Choline kinase--more than a cancer therapy target? Nat Rev Rheumatol (2014) 0.78
Choline metabolic profiling by magnetic resonance spectroscopy. Methods Mol Biol (2013) 0.82
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. J Exp Clin Cancer Res (2016) 0.78
Inhibition of Phosphatidylcholine-Specific Phospholipase C Interferes with Proliferation and Survival of Tumor Initiating Cells in Squamous Cell Carcinoma. PLoS One (2015) 0.78
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. Immunol Lett (2015) 0.77
H2S-releasing nanoemulsions: a new formulation to inhibit tumor cells proliferation and improve tissue repair. Oncotarget (2016) 0.75
Phosphatidylcholine-specific phospholipase C inhibition down- regulates CXCR4 expression and interferes with proliferation, invasion and glycolysis in glioma cells. PLoS One (2017) 0.75